查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465113

月經症候群治療藥物市場：按藥物類型、類型和分銷管道分類 - 全球預測 2024-2030

Premenstrual Syndrome Treatment Market by Drug Type (Antidepressants, Diuretics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs)), Type (Over-the-Counter, Prescription), Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

月經症候群治療市場規模預計2023年為17.2億美元，2024年達17.9億美元，預計2030年將達到23.2億美元，複合年成長率為4.35%。

月經症候群 (PMS) 包括女性月經週期前幾週出現的一系列身體、精神和情緒變化和症狀。不同女性的症狀差異很大，對日常生活和生活品質有重大影響。因此，經前症候群的治療是多方面和個人化的，旨在緩解特定症狀並改善整體健康。這些措施包括生活方式調整、飲食改善、壓力管理和藥物干預。人們對經前症候群及其對婦女健康和福祉的影響的認知和教育的增加，以及社會對月經健康和福祉態度的變化，增加了對綜合治療方法的需求。醫學研究的進步將帶來更有效和個人化的治療，政府對改善醫療保健基礎設施和可近性（包括遠端醫療服務）的支持將鼓勵更多女性接受治療。然而，圍繞新的和現有的治療方法的監管障礙和安全問題可能會阻礙 PMS 治療方法的普及。此外，經前症候群的症狀和治療效果各不相同，導致標準化治療困難。然而，大公司正在開發針對個人遺傳、荷爾蒙和生活方式因素的治療方法，並研究副作用較少的有效自然療法、飲食和生活方式干涉措施。創建用於症狀追蹤、治療和治療計劃的數位平台和應用程式可以進一步支持女性採用經前症候群治療方案。

主要市場統計
基準年[2023] 17.2億美元
預測年份 [2024] 17.9億美元
預測年份 [2030] 23.2億美元
複合年成長率（%） 4.35%

藥物類型：由於口服避孕藥具有避孕和症狀管理的雙重作用，用於經前症候群症狀管理的口服避孕藥的使用越來越多。

止痛藥，特別非類固醇消炎劑(NSAID)，是經前症候群藥物治療的重要組成部分，因為它們通常用於緩解與經前症候群相關的身體不適和疼痛。這些藥物透過抑制Gland的產生來有效減輕痙攣、乳房脹痛和肌肉疼痛，前列腺素會引起發炎和疼痛。選擇性血清素再回收抑制劑(SSRI) 是用於經前症候群管理的重要抗憂鬱症，專門針對與情緒和心境相關的症狀。 SSRIs 會增加大腦中的血清素水平，血清素是影響情緒和社交行為的神經傳導物質。 SSRI 對患有嚴重月經煩躁症（PMDD）（一種經前症候群的極端型態）的女性特別有用，並且已被證明可以有效減少煩躁、情緒低落、憂鬱和焦慮。口服避孕藥（避孕藥）和卵巢抑制劑通常用於治療經前症候群和經前憂鬱症。這些藥物透過調節或抑制排卵來發揮作用，從而抑制引發經前症候群症狀的荷爾蒙波動。口服避孕藥結合使用雌激素和黃體素來平衡荷爾蒙並減輕身體和心理症狀的嚴重程度。另一方面，促性腺激素分泌釋放激素 (GnRH)促效劑是另一類卵巢抑制藥物，可顯著減少卵巢激素的產生，通常用於嚴重的經前憂鬱症病例。

分銷管道：消費者對便利購物的需求導致了對電商分銷管道的偏好。

電子商務平台已成為經月經症候群（PMS）藥物的重要通路。這些管道可以幫助您輕鬆獲得全球範圍內的各種經前症候群治療方案。顧客喜歡在舒適的家中瀏覽和購買產品的便利性。此外，電子商務平台通常提供詳細的產品資訊、評論和比較，以幫助消費者做出明智的決定。對於尋求經前症候群治療方案的個人來說，謹慎購買和接收產品的能力增加了該管道的吸引力。零售藥局仍是經前症候群治療的重要通路。這種傳統管道使消費者可以輕鬆獲得成藥(OTC) 和處方箋藥。藥師在提供專業建議、回答問題和提出管理經前症候群症狀的建議方面發揮著重要作用。零售藥局憑藉現成的產品和與醫療保健專業人員的個人互動，已成為許多人的首選。此外，零售藥局通常備有多種產品，以滿足各種患者的偏好和治療要求。

區域洞察

在美洲，美國和加拿大是PMS治療的領先國家，其特點是高度認可和重視製藥和醫療領域的研發。美國的特點是治療方法多樣化，包括成藥）、處方藥和天然補充品，代表了一個重視個人選擇和整體健康的國家。美洲國家繼續投資數位健康解決方案，包括用於經前症候群追蹤和管理的行動應用程式。歐盟國家對實證醫學有著強烈的偏好，並且對自然療法和替代療法的興趣與日俱增。個人化醫療也有一個明顯的趨勢，即使用基因檢測來客製化經前症候群治療。歐盟對醫療設備、製劑和藥品的開發和效率的嚴格監管為歐盟地區的創新創建了標準化架構。文化敏感度和獲得醫療保健的不同程度影響著中東和非洲地區的治療格局。在亞太地區，中國、日本和印度等國家引領市場，對解決經前症候群的認知和開放程度不斷提高。在中國和印度，傳統治療方法和草藥仍然佔有重要地位。然而，人們越來越轉向臨床核准的藥物和整體健康方法。特別是在印度和中國，對女性健康新興企業的投資正在增加，反映出市場潛力不斷成長。

FPNV定位矩陣

FPNV定位矩陣對於評估月經症候群治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對經月經症候群治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.經月經症候群治療藥物市場規模及預測為何？

2.經月經症候群治療藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.月經症候群治療藥物市場的技術趨勢和法規結構是什麼？

4.經月經症候群治療藥物市場主要供應商的市場佔有率為何？

5.進入經月經症候群藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 提高對經月經症候群相關診斷的認知
      • 透過線上管道輕鬆獲得經前症候群治療產品
    • 抑制因素
      • 與 PMS 藥品和設備產品召回相關的問題
    • 機會
      • 經前症候群治療的進展與新藥的出現
      • 穿戴式科技的引入和數位健康的普及
    • 任務
      • 有關經前症候群管理的社會障礙和恥辱
  • 市場區隔分析
    • 藥物類型：由於口服避孕藥具有避孕和症狀管理的雙重作用，因此擴大用於管理經前症候群症狀。
    • 分銷管道：由於顧客便捷的購物需求，電子商務分銷管道正成為首選。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章依藥物類型分類的月經症候群治療藥物市場

  • 抗憂鬱症
  • 利尿劑
  • 非類固醇消炎劑(NSAID)
  • 口服避孕藥和卵巢抑制劑

第7章月經症候群治療藥物市場：依類型

  • 在商店
  • 處方箋

第8章月經症候群治療藥物市場：按分銷管道

  • 電子商務
  • 醫院
  • 零售藥房

第9章北美和南美月經症候群治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太經月經症候群治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲月經症候群治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Vistagene 宣布 PH80 用於急性管理經月經焦慮症症狀的探索性 2A 期研究取得正面結果
    • 三十麥迪遜醫院將透過從 Pill Club 策略收購資產，為數千名患者提供連續性護理，並加強其在女性健康領域的地位。
    • 總部位於倫敦的神經科技Start-Ups開發治療月經症狀的醫療設備
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4F1ADAF481D9

[192 Pages Report] The Premenstrual Syndrome Treatment Market size was estimated at USD 1.72 billion in 2023 and expected to reach USD 1.79 billion in 2024, at a CAGR 4.35% to reach USD 2.32 billion by 2030.

Premenstrual syndrome (PMS) comprises a range of physical, mental, and emotional changes or symptoms that occur in the few weeks before a woman's menstrual cycle. Symptoms may vary widely among women and can significantly impact daily functioning activities and quality of life. Treatment for PMS is thus multifaceted and personalized, aiming to alleviate specific symptoms and improve overall well-being. It ranges from lifestyle adjustments, dietary changes, and stress management to pharmacological interventions. Increased awareness and education about PMS and its impact on women's health and well-being and changing societal attitudes towards menstrual health and wellness have accentuated the need for comprehensive treatment options. Advances in medical research lead to more effective and personalized treatments, and government support for facilitating improvements in healthcare infrastructure and accessibility, including telehealth services, has encouraged more women to seek treatment. However, regulatory hurdles and safety concerns surrounding new and existing treatments may impede the widespread adoption of PMS treatment. Furthermore, variability in PMS symptoms and treatment efficacy makes standardized treatments challenging. However, key players are developing treatments that are tailored to individual genetic, hormonal, and lifestyle factors and researching effective natural, dietary, and lifestyle interventions that have fewer side effects. Creating digital platforms and apps for symptom tracking, therapy, and treatment plans can further boost the adoption of PMS treatment options among women,

KEY MARKET STATISTICS
Base Year [2023] USD 1.72 billion
Estimated Year [2024] USD 1.79 billion
Forecast Year [2030] USD 2.32 billion
CAGR (%) 4.35%

Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management

Analgesics, particularly nonsteroidal anti-inflammatory drugs (NSAIDs), are an essential component in the pharmacological treatment of PMS as they are commonly used to alleviate physical discomfort and pain associated with PMS. These medications are effective in reducing cramps, breast tenderness, and muscle pain by inhibiting the production of prostaglandins, substances known to cause inflammation and pain. Selective serotonin reuptake inhibitors (SSRIs) represent prominent antidepressants prescribed for PMS management, specifically targeting emotional and mood-related symptoms. SSRIs increase the levels of serotonin in the brain, a neurotransmitter that can affect mood and social behavior. They are particularly useful for women experiencing severe pre-menstrual dysphoric disorder (PMDD), a more extreme form of PMS, and have shown efficacy in reducing irritability, mood swings, depression, and anxiety. Oral contraceptives (birth control pills) and ovarian suppression agents are frequently utilized in PMS and PMDD treatment. These medications work by regulating or suppressing ovulation and, therefore, hormonal fluctuations that can trigger PMS symptoms. Oral contraceptives, combined with estrogen and progestin, help in achieving hormone balance, reducing the severity of physical and emotional symptoms. Meanwhile, gonadotropin-releasing hormone (GnRH) agonists are another class of ovarian suppression agents that significantly reduce ovarian hormone production and are often used in severe cases of PMDD.

Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping

The e-Commerce platform has emerged as a significant distribution channel for premenstrual syndrome (PMS) treatment products. This channel facilitates easy access to a wide range of PMS treatment options available across the globe. Customers appreciate the convenience of browsing and purchasing products from the comfort of their own homes. Moreover, e-Commerce platforms often offer detailed product information, reviews, and comparisons, assisting consumers in making informed decisions. The ability to discreetly purchase and receive products enhances the appeal of this channel for individuals seeking PMS treatment options. Retail pharmacies remain a crucial distribution channel for PMS treatment products. This traditional channel allows consumers to obtain over-the-counter (OTC) and prescription medications with ease. Pharmacists play an integral role by providing professional advice, answering questions, and offering recommendations for managing PMS symptoms. The immediate availability of products and personal interaction with healthcare professionals make retail pharmacies a preferred choice for many individuals. In addition, retail pharmacies often stock a wide range of products and cater to various patient preferences and treatment requirements.

Regional Insights

In the Americas, the U.S. and Canada represent key nations for PMS treatment, characterized by high awareness and a strong focus on research and development in the pharmaceutical and medical sectors. The U.S. is notable for its diversity in treatment approaches, including over-the-counter (OTC) medications, prescription drugs, and natural supplements, representing the country's emphasis on personal choice and holistic health. Countries in the Americas witness ongoing investment in digital health solutions, such as mobile apps for PMS tracking and management. EU countries exhibit a strong preference for evidence-based medicine with a growing interest in natural and alternative treatments and a focus on advancing cutting-edge research in the realm of healthcare technology. There is a notable trend towards personalized medicine, leveraging genetic testing to tailor PMS treatment. Stringent regulations for the development and efficiency of medical devices, pharmaceutical preparations, and drugs in the EU have created a standardized architecture for innovations in the EU region. In the Middle East and Africa, cultural sensitivities and varying levels of healthcare accessibility impact the treatment landscape. The Asia Pacific region showcases a growing awareness and openness towards addressing PMS, with countries such as China, Japan, and India leading the market. Traditional remedies and herbal treatments still hold significant importance in China and India. However, there is an increasing shift towards clinically approved medications and holistic wellness approaches. Investment in women's health startups, particularly in India and China, has seen a rise, reflecting the growing market potential.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Premenstrual Syndrome Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Premenstrual Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Premenstrual Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Alfa Pharma GmbH, Asarina Pharma AB., ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma, Bayer AG, Cadila Pharmaceuticals., Comforte Cream by PMS4PMS, LLC, Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Mylan N.V., Par Pharmaceutical, Inc, Pfizer Inc., Samphire Neuroscience, Shine Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Himalaya Drug Company, and Vitane Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Premenstrual Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Antidepressants
    • Diuretics
    • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • Oral Contraceptives & Ovarian Suppression Agents
  • Type
    • Over-the-Counter
    • Prescription
  • Distribution Channel
    • E-commerce
    • Hospitals
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Premenstrual Syndrome Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Premenstrual Syndrome Treatment Market?

3. What are the technology trends and regulatory frameworks in the Premenstrual Syndrome Treatment Market?

4. What is the market share of the leading vendors in the Premenstrual Syndrome Treatment Market?

5. Which modes and strategic moves are suitable for entering the Premenstrual Syndrome Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness of diagnosis regarding premenstrual syndrome
      • 5.1.1.2. Easy availability of PMS treatment products through online channels
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls for PMS drugs and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapy for PMS and the emergence of novel drugs
      • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
    • 5.1.4. Challenges
      • 5.1.4.1. Societal barriers and stigmatization regarding PMS management
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management
    • 5.2.2. Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Premenstrual Syndrome Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antidepressants
  • 6.3. Diuretics
  • 6.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 6.5. Oral Contraceptives & Ovarian Suppression Agents

7. Premenstrual Syndrome Treatment Market, by Type

  • 7.1. Introduction
  • 7.2. Over-the-Counter
  • 7.3. Prescription

8. Premenstrual Syndrome Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospitals
  • 8.4. Retail Pharmacies

9. Americas Premenstrual Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Premenstrual Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Premenstrual Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
    • 12.3.2. Thirty Madison Delivers Continuity Of Care For Thousands Through Strategic Asset Purchase From The Pill Club, Strengthening Its Position In Women's Health
    • 12.3.3. London-Based Neurotech Start-Up Develops Medical Device For Menstrual Symptoms
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PREMENSTRUAL SYNDROME TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023